recombinant human fgf23 (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
recombinant human fgf23
Recombinant Human Fgf23, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 46 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf23/Recombinant+Human+FGF-23+Protein/pmc12929185-42-0-6
Average 94 stars, based on 46 article reviews
Recombinant Human Fgf23, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 46 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+fgf23/Recombinant+Human+FGF-23+Protein/pmc12929185-42-0-6
Average 94 stars, based on 46 article reviews
recombinant human fgf23 - by Bioz Stars,
2026-10
94/100 stars
Images
1) Product Images from "The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease"
Article Title: The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease
Journal: Journal of Cell Communication and Signaling
doi: 10.1002/ccs3.70061
Figure Legend Snippet: Anti‐GBM disease causes tubular damage and partial renal resistance to FGF23. (A) Depicts the experimental workflow in male C57BL/6 mice undergoing induction of anti‐GBM disease using nephrotoxic serum followed by 6 days of intravenous (IV) FGF23 or vehicle treatment. (B) Shows the glomerular filtration rate of different experimental groups at days 0 and 7. (C) Shows urinary albumin/creatinine ratio at day 7. (D) Shows the example renal sections negative or positive for renal tubular casts (arrows) and quantitative tubular cast scores. (E) Shows plasma phosphate and fractional excretion of phosphate of healthy mice and mice with anti‐GBM treated with vehicle or FGF23. Analyses in panel (B): paired t ‐test. Analyses in panels (C–E): two‐way ANOVA. Anti‐GBM, anti‐glomerular basement membrane; d, disease state; t, treatment.
Techniques Used: Filtration, Clinical Proteomics, Membrane
Figure Legend Snippet: Six‐day course of FGF23 treatment induces renal transcriptional signatures of inflammatory responses and injury. (A) Indicates the number of differentially expressed genes according to experimental comparison in renal bulk RNA‐Seq. (B, C) Depict volcano plots of DEGs above a cutoff of adjusted p < 0.05 and log2‐fold change >1, in the comparison of FGF23 versus vehicle effect in mice with anti‐GBM (B) and the interaction between treatment and disease effect (C). (D–F) Depict significant Reactome gene set enrichment analyses of FGF23 effects in healthy mice (D), mice with anti‐GBM disease (E), and the interaction between treatment and disease effect (F). (G) Depicts a network of ligand–receptor interaction pairs that were significant for FGF23 versus vehicle comparisons in mice with anti‐GBM disease by bulk RNA‐Seq. The ligand–receptor interactions were inferred using R/BulkSignalR. Anti‐GBM, anti‐glomerular basement membrane disease. N = 3 for anti‐GBM groups and n = 4 for healthy groups.
Techniques Used: Comparison, RNA Sequencing, Membrane
Figure Legend Snippet: Bulk RNA‐Seq deconvolution and immunofluorescence staining reveal an FGF23‐driven increase in overall immune cell and macrophage abundance in the kidneys of mice with anti‐GBM disease. (A, B) Depict the annotation of renal cell clusters in the reanalysis of the single‐cell RNA‐Seq dataset GSE107585 of murine kidney from 7 sex‐mixed healthy C57BL/6 mice; see also Supporting Information Figure . (C) Shows a wedding pie plot of the bulk deconvolution of the renal cellular composition according to FGF23 treatment and anti‐GBM disease state, as indicated by labels. Overall renal immune cells and macrophage‐like cells are displayed by bulk deconvolution (D, G) and by immunofluorescence with automated quantification for CD45 (E, F) and F4/80 (H, I). RNA‐Seq: N = 3 for anti‐GBM groups and n = 4 for healthy groups. Immunofluorescence: n = 4 per group. Statistical analysis: two‐way ANOVA. anti‐GBM, anti‐glomerular basement membrane disease; Baso, basophil; CD, collecting duct; d, disease state; DCT, distal convoluted tubule; DLOH, descending limb of Henle; EC, endothelial cell; Granul, granulocyte; i, interaction; IC, intercalated cells; Ly, lymphocyte; Mono, monocyte; Mph, macrophage; NK, natural killer cell; PC, principal cells; PT, proximal tubule; S, segment; t, treatment.
Techniques Used: RNA Sequencing, Immunofluorescence, Staining, Single Cell, Membrane
Figure Legend Snippet: Immune protein profiling highlights an increase in circulating soluble tumor necrosis factor receptors induced by FGF23 and anti‐GBM disease in mice. A plasma cytokine protein array shows FGF23 effects in healthy male C57BL/6 mice (A) and in mice treated with nephrotoxic serum to induce anti‐GBM disease (B). The interaction between treatment and disease state (C) and the overall disease effect (D) are shown. (E–F) Depict analyses of soluble TNF receptors 1 and 2 by two‐way ANOVA. d, disease state; t, treatment. N = 4 biologically independent replicates per group. Anti‐GBM, anti‐glomerular basement membrane.
Techniques Used: Clinical Proteomics, Protein Array, Membrane
Figure Legend Snippet: Renal immune cell recruitment driven by FGF23 excess is exposure time dependent. Renal microarray transcriptome datasets GDS3361 of male Fgf23 transgenic and control mice or sex‐matched Hyp mice of dataset GDS879 (B) underwent bulk deconvolution with reference to single‐cell RNA‐Seq dataset GSE107585 of murine kidney from 7 sex‐mixed healthy C57BL/6 mice and, subsequently, visualization of overall fractions of inferred immune cells and macrophage‐like cells, as indicated. (C) Shows the experimental workflow of experiments with female BALB/c mice undergoing Adriamycin (doxorubicin) nephropathy followed by a single intravenous (IV) injection of FGF23 or vehicle. (D) Shows the urinary albumin/creatinine ratio 7 days after induction of Adriamycin nephropathy. Statistical analysis: two‐way ANOVA. d, disease state. (E–G) Show significant Reactome gene set enrichment analyses of renal FGF23 effects in healthy mice (E), mice with Adriamycin nephropathy (F), and the interaction between treatment and disease effect (G). (H) Depicts the log‐fold change of 8 transcripts with lowest adjusted p ‐value in the interaction analysis of FGF23 effect in diseased versus FGF23 effect in healthy mice in a 2 × 2 factorial design. N = 5 (A), 10 (B), or 4 (C–H) biologically independent replicates per group.
Techniques Used: Microarray, Transgenic Assay, Control, Single Cell, RNA Sequencing, IV Injection
Figure Legend Snippet: Intrarenal proinflammatory effects of FGF23 applied ex vivo in PCKS. (A) Male DBA/2J mice underwent dietary treatment with 0.2% adenine for 15 weeks, followed by organ collection and preparation of 300 µm PCKS for a 24‐h treatment with FGF23 or vehicle ex vivo. No disease‐free controls were used for this substudy. (B) Depicts the fibrotic changes in a representative 4 µm section of PCKS stained with hematoxylin and eosin (left scale bar, 500 µm; right, 100 µm). (C) Shows the log‐fold change of upregulated transcripts with the lowest adjusted p ‐value in the FGF23 versus vehicle comparison. (D–F) Show gene set enrichment analyses of FGF23 effects in Reactome (D), WikiPathways (E), and Pathway Interaction Database (F) gene sets. N = 4 biologically independent replicates per group. PCKS, precision‐cut kidney slices.
Techniques Used: Ex Vivo, Staining, Comparison
Figure Legend Snippet: FGF23 is associated with renal immune cell content in human patients with IgA nephropathy. As a reference, single‐nucleus RNA‐Seq data from 5 human kidney biopsies ( GSE199711 ) of 2 healthy controls and 3 patients with chronic kidney disease (CKD) were reanalyzed and annotated (A); see also Supporting Information Figure . 35 patients with IgA nephropathy from the Karolinska Kidney Biopsy Cohort showed an inverse univariable association between circulating FGF23 and measured glomerular filtration rate (GFR) (B). The associations between transcriptome‐inferred renal fibroblasts and immune cells (C–D) or macrophages (E–F) and circulating FGF23 are shown, with adjustment for GFR, 25OH‐vitamin D and parathyroid hormone. (D, F) Show disaggregated data stratified by GFR in CKD stages I–II and III–V.
Techniques Used: RNA Sequencing, Filtration
Related Articles
Recombinant:Article Title: Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism Article Snippet: Human recombinant FGF2 was purchased from Life Technologies (Grand Island, NY). .. Recombinant human FGF21, Article Title: Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism. Article Snippet: Human recombinant FGF2 was purchased from Life Technologies (Grand Island, NY). .. Recombinant human FGF21, Article Title: Fibroblast Growth Factor 23 drives MMP13 expression in human osteoarthritic chondrocytes in a Klotho-independent manner. Article Snippet: .. They were cultured as first-passage monolayer25 in experiments where OA 115 chondrocytes were challenged with 10 to 100 ng/ml of recombinant Article Title: FGF23 ameliorates ischemia-reperfusion induced acute kidney injury via modulation of endothelial progenitor cells: targeting SDF-1/CXCR4 signaling Article Snippet: .. After serum starvation (0.5% FBS), the EPCs were treated with 100 ng/ml of recombinant SDF-1 (R&D) and 1 nM of recombinant Article Title: Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain Article Snippet: APT-F2P used for animal experiments was 5′ and 3′ conjugated with 40-kDa PEG (SUNBRIGHT GL2-400TS, NOF Corporation, Tokyo, Japan) and an inverted dT (idT), respectively, were prepared by chemical synthesis (Gene Design, Ibaraki, Japan). .. Growth factors used are: recombinant human FGF1 (PEPROTECH, Rocky Hill, KY), human FGF2 (PEPROTECH), human FGF6 (R&D Systems, Minneapolis, MN), human FGF9 (R&D Systems), Article Title: Klotho Supplementation Reverses Renal Dysfunction and Interstitial Fibrosis in Remnant Kidney. Article Snippet: .. In the third series of experiments, intervention was given with or without recombinant Article Title: FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis Article Snippet: .. The next day, NRVM and NRCF were stimulated for 48 h with recombinant Derivative Assay:Article Title: miR-129 Blocks Secondary Hyperparathyroidism-Inducing Fgf23/αKlotho Signaling in Mice with Chronic Kidney Disease. Article Snippet: Background: Secondary hyperparathyroidism, a condition of excess parathyroid hormone (PTH, Pth) production, is often seen in chronic kidney disease (CKD) patients with elevated fibroblast growth factor 23 (FGF23, Fgf23).. Elevated FGF23 levels stimulate secondary hyperparathyroidism-associated parathyroid aKlotho signaling.. As overexpression of rationally selected microRNAs can suppress target gene activation, we hypothesized that microRNA-based suppression of parathyroid FGF23/ aKlotho axis activity may be a potential strategy to combat secondary hyperparathyroidism. Modification:Article Title: miR-129 Blocks Secondary Hyperparathyroidism-Inducing Fgf23/αKlotho Signaling in Mice with Chronic Kidney Disease. Article Snippet: Background: Secondary hyperparathyroidism, a condition of excess parathyroid hormone (PTH, Pth) production, is often seen in chronic kidney disease (CKD) patients with elevated fibroblast growth factor 23 (FGF23, Fgf23).. Elevated FGF23 levels stimulate secondary hyperparathyroidism-associated parathyroid aKlotho signaling.. As overexpression of rationally selected microRNAs can suppress target gene activation, we hypothesized that microRNA-based suppression of parathyroid FGF23/ aKlotho axis activity may be a potential strategy to combat secondary hyperparathyroidism. Cell Culture:Article Title: Fibroblast Growth Factor 23 drives MMP13 expression in human osteoarthritic chondrocytes in a Klotho-independent manner. Article Snippet: .. They were cultured as first-passage monolayer25 in experiments where OA 115 chondrocytes were challenged with 10 to 100 ng/ml of recombinant Transfection:Article Title: Klotho Supplementation Reverses Renal Dysfunction and Interstitial Fibrosis in Remnant Kidney. Article Snippet: .. In the third series of experiments, intervention was given with or without recombinant |
